{
    "name": "elosulfase alfa",
    "comment": "Rx",
    "other_names": [
        "Vimizim"
    ],
    "classes": [
        "Enzymes",
        "Metabolic"
    ],
    "source": "https://reference.medscape.com/drug/vimizim-elosulfase-alfa-999909",
    "pregnancy": {
        "common": [
            "There is a Morquio A Registry that collects data on pregnant women with MPS IVA who are treated with elosulfase alfa; contact MARS@bmrn.com or call 1-800-983-4587 for information and enrollment",
            "Available data from published case reports and postmarketing experience in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In animal reproduction studies, no effects on embryo-fetal development were observed in rats given daily administration of elosulfase alfa up to 33 times the human steady-state AUC at the recommended human weekly dose premating and through the period of organogenesis",
                    "No effects on embryo-fetal development were observed in rabbits given daily administration of elosulfase alfa at doses up to 8 times the human steady-state AUC at the recommended weekly dose during organogenesis, which produced maternal toxicity",
                    "A dose dependent increase in stillbirths was observed when elosulfase alfa was administered daily in rats during organogenesis through lactation at doses 5 times the human steady-state AUC at the recommended human weekly dose; an increase in pup mortality was observed at doses producing maternal toxicity"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Pregnancy can exacerbate preexisting clinical manifestations of MPS and lead to adverse outcomes for both mother and fetus"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available on the presence of elosulfase alfa in human milk or the effects on milk production",
            "Elosulfase alfa is present in milk from treated rats; when a drug is present in animal milk, it is likely that the drug will be present in human milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Anaphylaxis",
                    "description": [
                        "Life-threatening anaphylactic reactions reported during IV infusion",
                        "Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (eg, nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment",
                        "Closely observe patients during and after administration and be prepared to manage anaphylaxis",
                        "Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur  Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Anaphylaxis reported and may occur as early as 30 minutes from the start of infusion and up to 3 hr after completing the infusion (see Black Box Warnings)",
                "Increased risk of acute respiratory complications; monitor patients with acute febrile or respiratory illness at the time of infusion (higher risk of life-threatening complications from hypersensitivity reaction)",
                "Sleep apnea is common in patients with MPS IVA, evaluate airway patency before initiating treatment with elosulfase alfa"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Pyrexia",
            "percent": "33"
        },
        {
            "name": "Vomiting",
            "percent": "31"
        },
        {
            "name": "Headache",
            "percent": "26"
        },
        {
            "name": "Nausea",
            "percent": "24"
        },
        {
            "name": "Abdominal pain",
            "percent": "21"
        },
        {
            "name": "Hypersensitivity",
            "percent": "18.7"
        },
        {
            "name": "including anaphylaxis",
            "percent": "10.3"
        },
        {
            "name": "Chills",
            "percent": "10.3"
        },
        {
            "name": "Fatigue",
            "percent": "7.7"
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        }
    ]
}